All In Biotech

Drug Trial Radar · NCT00768300

(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

ARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF)

Last checked: Nov 20, 2026Latest source record: Apr 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 494 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

494

Actual

Start

Dec 2008

Primary completion

Feb 2011

Study completion Feb 2011

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Oct 8, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ARTEMIS-IPF study was conducted to determine if ambrisentan was effective in delaying disease progression and death in participants with idiopathic pulmonary fibrosis (IPF), to evaluate its safety, and to evaluate its effect on development of pulmonary hypertension, quality of life, and dyspnea (shortness of breath) symptoms in this participant population. Participants were randomized in a 2:1 ratio to receive ambrisentan or placebo, respectively. Participation in the study was to be up to 4 years, depending on how long it would take to enroll participants and observe study events. After randomization, visits to the clinic took place every 3 months, and laboratory procedures were performed every month.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • AmbrisentanDrug

    Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.

  • PlaceboDrug

    Placebo to match ambrisentan was administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Death or Disease (IPF) Progression.Time frame: Up to 48 months

Locations

185 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Hospital

    Birmingham, Alabama

  • Pulmonary Associates

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • David Geffen School of Medicine at UCLA(Harbor-UCLA Medical Center)

    Los Angeles, California

  • University of California, Davis

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Stanford University

    Stanford, California

  • National Jewish Medical And Research Center

    Denver, Colorado

  • Site not named

    Newark, Delaware

  • Bay Area Chest Physicians

    Clearwater, Florida

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Site not named

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • Site not named

    Council Bluffs, Iowa

  • Kentuckiana Pulmonary Association

    Louisville, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Saint Lukes Foundation

    Chesterfield, Missouri

  • Dartmouth Medical School

    Lebanon, New Hampshire

  • Site not named

    New Brunswick, New Jersey

  • Site not named

    Piscataway, New Jersey

  • Pulmonary & Allergy Associates

    Summit, New Jersey

  • Pulmonary And Critical Care Services, P.C.

    Albany, New York

  • Winthrop University Hospital

    Mineola, New York

  • Site not named

    New Hyde Park, New York

  • Site not named

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Site not named

    Cincinnati, Ohio

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • The Oregon Clinic, P.C.

    Portland, Oregon

  • University of Pennsylvania Health Systems

    Philadelphia, Pennsylvania

Showing 40 of 185 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.